{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:36:53Z","timestamp":1789522613306,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T00:00:00Z","timestamp":1449532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ejca.2015.11.021","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T21:25:33Z","timestamp":1453238733000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer"],"prefix":"10.1016","volume":"56","clinical-trial-number":[{"clinical-trial-number":"nct01158404","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Shubham","family":"Pant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne F.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla D.","family":"Kurkjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald S.","family":"McMeekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim A.","family":"Benhadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharvin K.R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Kursar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej J.","family":"Zamek-Gliszczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.M.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C.","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.11.021_bib1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nrc1186","article-title":"The role of Notch in tumorigenesis: oncogene or tumour suppressor?","volume":"3","author":"Radtke","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2015.11.021_bib2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.284.5415.770","article-title":"Notch signaling: cell fate control and signal integration in development","volume":"284","author":"Artavanis-Tsakonas","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ejca.2015.11.021_bib3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1254\/fpj.136.204","article-title":"Current status of VEGF-targeted therapy and multiple-targeted receptor tyrosine kinase inhibitors targeting VEGF and FGF-receptors","volume":"136","author":"Funahashi","year":"2010","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.ejca.2015.11.021_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/onc.2009.366","article-title":"Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim","volume":"29","author":"Konishi","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2015.11.021_bib5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/carcin\/bgn079","article-title":"Notch-1 regulates transcription of the epidermal growth factor receptor through p53","volume":"29","author":"Purow","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2015.11.021_bib6","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.bbagen.2012.08.009","article-title":"Sending the right signal: Notch and stem cells","volume":"1830","author":"Perdigoto","year":"2013","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.ejca.2015.11.021_bib7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2174\/138920310791824039","article-title":"Notch signaling proteins: legitimate targets for cancer therapy","volume":"11","author":"Wang","year":"2010","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.ejca.2015.11.021_bib8","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1038\/onc.2008.223","article-title":"More complicated than it looks: assembly of Notch pathway transcription complexes","volume":"27","author":"Kovall","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2015.11.021_bib9","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1007\/s00018-007-7164-1","article-title":"Notch and cancer: a double-edged sword","volume":"64","author":"Koch","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ejca.2015.11.021_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2015.11.021_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-1-4614-0899-4_18","article-title":"Notch signaling and breast cancer","volume":"727","author":"Reedijk","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ejca.2015.11.021_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2015.11.021_bib13","doi-asserted-by":"crossref","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","article-title":"Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy","volume":"109","author":"McAuliffe","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2015.11.021_bib14","series-title":"Data on file","author":"Eli Lilly and Company","year":"2015"},{"issue":"8 suppl.","key":"10.1016\/j.ejca.2015.11.021_bib15","article-title":"Novel inhibitor of Notch signaling for the treatment of cancer","volume":"73","author":"Bender","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2015.11.021_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"10.1016\/j.ejca.2015.11.021_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.11.021_bib18","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/sim.4780131802","article-title":"A comparison of two phase I trial designs","volume":"13","author":"Korn","year":"1994","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2015.11.021_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O'Quigley","year":"1990","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2015.11.021_bib20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/sim.4780141102","article-title":"Some practical improvements in the continual reassessment method for phase I studies","volume":"14","author":"Goodman","year":"1995","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2015.11.021_bib21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/sim.4780140909","article-title":"An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses","volume":"14","author":"Moller","year":"1995","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2015.11.021_bib22","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/sim.4780101104","article-title":"Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study","volume":"10","author":"O'Quigley","year":"1991","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2015.11.021_bib23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s002800050763","article-title":"Practical implementation of a modified continual reassessment method for dose-finding trials","volume":"41","author":"Piantadosi","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2015.11.021_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/10543409408835079","article-title":"Practical modifications of the continual reassessment method for phase I cancer clinical trials","volume":"4","author":"Faries","year":"1994","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.ejca.2015.11.021_bib25","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1307::AID-SIM128>3.0.CO;2-X","article-title":"Adaptive design improvements in the continual reassessment method for phase I studies","volume":"18","author":"Heyd","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2015.11.021_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2015.11.021_bib27","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/1535-7163.MCT-10-0034","article-title":"Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design","volume":"9","author":"Wei","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2015.11.021_bib28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/0008-5472.CAN-08-2088","article-title":"Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity","volume":"69","author":"Meng","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2015.11.021_bib29","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/leu.2009.75","article-title":"NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia","volume":"23","author":"Real","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2015.11.021_bib30","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/cncr.21904","article-title":"Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells","volume":"106","author":"Wang","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2015.11.021_bib31","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/ijc.21589","article-title":"Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells","volume":"118","author":"Wang","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2015.11.021_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2015.11.021_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10637-013-9965-4","article-title":"A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078\/CTEP 8575)","volume":"32","author":"Richter","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2015.11.021_bib34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.109.030841","article-title":"Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans","volume":"38","author":"Yi","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejca.2015.11.021_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/BF02353483","article-title":"Characterization of four basic models of indirect pharmacodynamic responses","volume":"24","author":"Sharma","year":"1996","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.ejca.2015.11.021_bib36","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/0008-5472.CAN-03-2524","article-title":"Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents","volume":"64","author":"Simeoni","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2015.11.021_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pharmthera.2013.09.005","article-title":"Targeting notch signaling pathway in cancer: clinical development advances and challenges","volume":"141","author":"Takebe","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejca.2015.11.021_bib38","doi-asserted-by":"crossref","first-page":"20630","DOI":"10.1074\/jbc.M114.579862","article-title":"\u00df-Site amyloid precursor protein cleaving enzyme 1(BACE1) regulates Notch signaling by controlling the cleavage of jagged 1 (Jag1) and jagged 2 (Jag2) proteins","volume":"289","author":"He","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2015.11.021_bib39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40261-012-0006-4","article-title":"Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Abeta levels in healthy young men","volume":"32","author":"Tong","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ejca.2015.11.021_bib40","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.clinthera.2012.01.022","article-title":"Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers","volume":"34","author":"Tong","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejca.2015.11.021_bib41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915011296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T03:26:35Z","timestamp":1537068395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915011296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":41,"alternative-id":["S0959804915011296"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.11.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}